Ketorolac-an Option for Post Operative Pain Management After Elective Cardiac Surgery.
Status:
Completed
Trial end date:
2021-07-06
Target enrollment:
Participant gender:
Summary
OBJECTIVE: The purpose of this study was to compare the efficacy of Ketorolac versus
Paracetamol as an adjunct to Nalbuphine in the management of post-operative pain following
elective cardiac surgery.
STUDY DESIGN: Randomized (single-blind) control trial.
SAMPLING TECHNIQUE: Computer generated, randomized selection of patients with 50% probability
of assignment into either group.
PLACE AND STUDY DURATION: (single center) SICU at the National Institute of Cardiovascular
Diseases Hospital, Karachi over a period of six months, from January 1, 2021 up to June 30,
2021.
METHODS: Sixty patients (30 in each group) were randomly assigned to receive either
Paracetamol (control) or Ketorolac (treatment), along with the usual Nalbuphine infusion,
over the first 48 hours postoperatively. The control group received injection Paracetamol 1gm
six hourly, whereas treatment group received injection Ketorolac 30mg eight hourly.
PRIMARY OUTCOME: The VAS (pain score) was evaluated at 6, 12, 18 and 24 hours post-extubation
and a score of 4 or less was taken as a cut-off for adequate pain control.
SECONDARY OUTCOMES: The time taken to extubation postoperatively. The total dose of
Nalbuphine administered to each patient and total chest tube drainage recorded over 48 hours
postoperatively.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Cardiovascular Diseases, Karachi